• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

France

Europe Euro European biotech European startup fundraising
Biotech

Sofinnova closes €165M European biotech acceleration fund

After raising 1.2 billion euros in 2024, Sofinnova Partners has closed a 165 million euro biotech acceleration fund with help from Amgen and Pfizer.
Fraiser Kansteiner Mar 18, 2025 4:01am
Stryker

Stryker to snag French joint replacement maker Serf SAS

Dec 18, 2023 11:07am
air mail par avion paper airplane la poste

Medtronic stamps healthcare data collab with France's La Poste

Oct 30, 2023 12:35pm
Paul Stoffels

Galapagos, following Sanofi's playbook, offloads R&D site to CRO

Mar 31, 2023 8:30am
Illustration of two people shaking hands standing on money and a lightbulb

Apax takes stake in CRO Porsolt, to grow staff 40% in 4 years

Feb 23, 2023 7:30am
success failure signposts

Lysogene's lead gene therapy fails phase 2/3 trial with cash low

Nov 18, 2022 3:12pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings